AI-powered breast cancer risk tool reaches U.S. women through Everlywell partnership

About 85% of breast cancers develop in women with no family history of the disease. No genetic red flags. No obvious warning signs. Just a diagnosis that arrives without context. That single statistic is what makes the commercial launch of Clairity Breast, now available through the Everlywell platform, worth paying close attention to.

Announced on October 1, 2026, the partnership between Everlywell and Clairity brings an FDA-authorized AI risk assessment tool to women across the United States who have had a qualifying screening mammogram in the past 12 months. Women can now access the tool directly through Everlywell's consumer platform, with results reviewed and released by a licensed clinician from Everlywell's affiliated provider network.

Both companies are female-founded and female-led. Clairity was founded by Dr. Connie Lehman, a professor of radiology at Harvard Medical School. Everlywell was founded by Julia Cheek, who built the company into what it describes as the top at-home lab testing brand in the United States. The alignment here is more than symbolic. It reflects a shared commercial and clinical bet: that women want, and will use, more information about their own health when it's made easy to access.

How does it work?

Clairity Breast analyzes a standard screening mammogram using AI and computer vision to detect subtle patterns in the image that are not visible to the human eye. From those patterns, it estimates a woman's risk of developing breast cancer over the next five years. The assessment does not screen for or detect cancer. It is a forward-looking risk estimate, designed to give women and their doctors a clearer basis for planning screening frequency and risk-reduction strategies.

Through the Everlywell platform, the process works as follows:

• A woman with a qualifying recent mammogram from the past 12 months accesses the tool through Everlywell's website
• A licensed provider in Everlywell's affiliated clinician network reviews and places the order
• Results are reviewed and released by a licensed provider, with next steps based on national guidelines
• The woman receives her result and can share it with her own physician to inform her care plan
• Everlywell's clinical team is available to answer follow-up questions about the result

Pricing details were not disclosed at the time of the announcement, but the service is available directly to consumers without requiring a referral from an existing provider.

Why does it matter?

Until this launch, Clairity Breast had limited availability, accessible only through specific health systems including Beth Israel Deaconess Medical Center in Massachusetts and Invision Sally Jobe in Colorado. That is now changing. By routing distribution through Everlywell's consumer platform, the tool becomes available to a far broader population of women, many of whom are already getting routine mammograms but receiving no risk estimate alongside them.

The clinical case for this approach is backed by recent guideline changes. In 2026, updated National Comprehensive Cancer Network guidelines introduced AI-based mammogram risk assessment as an option for identifying women at increased risk, starting at age 35. Clairity Breast is already included in NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Screening and Diagnosis. So the clinical framework exists. The gap has been access.

Dr. Lehman put it plainly: the information needed to assess breast cancer risk has been inside every mammogram image all along. The technology to interpret it simply didn't exist in a usable, authorized form until now.

The context

Clairity Breast received FDA De Novo authorization in May 2025, the first AI-based tool to receive that designation for predicting five-year breast cancer risk from a standard mammogram. It was validated in more than 77,000 mammograms across five U.S. sites for the authorization process, and subsequently validated in more than 120,000 mammograms across 10 U.S. facilities after authorization. That is a substantial clinical evidence base for a tool that is still relatively new to the market.

For Everlywell, the addition of Clairity Breast fits into a growing cancer-focused portfolio that also includes at-home colon cancer screening, an at-home HPV self-collection kit for cervical cancer screening, and access to multi-cancer early detection testing. The company reports delivering close to one billion personalized health insights and reaching more than 60 million people since its founding.

The broader trend this reflects is one gaining traction across healthcare systems globally: moving risk assessment earlier in the care pathway, before a diagnosis, rather than after. For health systems and policymakers focused on preventive care, the combination of FDA authorization, updated clinical guidelines, and consumer-facing distribution is a meaningful step in that direction. And for the many women who fall into that 85% with no family history, it may be the first time a routine mammogram tells them something genuinely new about their future health.